qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:314e4cbfa3bb0a4732f16295 | QAG:1d81fbce298a3d396f695326 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "It was also found in our study that obtaining MPR after neoadjuvant therapy was associated with better survival outcomes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pass... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:23cd3794bfc615b1102681c8","quotes":["It was also found in our study that obtaining MPR after neoadjuvant therapy ... | [
"CLM:23cd3794bfc615b1102681c8",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC9606329"
] | [
"SPAN:2461310ab0bd3a9035bcab47",
"SPAN:d79f58948a7339d072d36344"
] | [] | [] | {"qa_id":"QA:314e4cbfa3bb0a4732f16295","qa_group_id":"QAG:1d81fbce298a3d396f695326","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"It was also found in our study that obtaining MPR after neoadjuvan... |
QA:3155254258a3055e890a8d28 | QAG:5067dad0c154d848ec11114f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "EC esophageal cancer ESCC esophageal squamous cell carcinoma NSCLC non-small cell lung cancer CPS comprehensive positive score TPS tumor proportion score PD-L1 programmed death receptor ligand 1 CT Computed tomography AI artificial intelligence ICI + CT immune-checkpoi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5589852f72813c4dcfe036ba","quotes":["EC esophageal cancer ESCC esophageal squamous cell ... | [
"CLM:5589852f72813c4dcfe036ba",
"CLM:08a48a247c9286d56048a968",
"CLM:580c824bceb1b0aeaa9fd109"
] | [
"PMCID:PMC8557514",
"PMCID:PMC8764510"
] | [
"SPAN:ed3b2dada6af97e4f5f93fd2",
"SPAN:71063e623dc78ac3a46296fa"
] | [
"ASC2:313457e3aaadb3f1440d4668"
] | [
"HYP:DCH:acb8169dcd8a8c2eeb4a62f0"
] | {"qa_id":"QA:3155254258a3055e890a8d28","qa_group_id":"QAG:5067dad0c154d848ec11114f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"EC esophageal cancer ESCC esophageal squamous cell carcinoma NSCLC... |
QA:336a82110bcf7b1b50e57f52 | QAG:71d80899025a69a2f35c6d92 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Although this is not the first study to use inflammatory and nutritional indexes to predict pCR, to our knowledge, the present study is the first report focused on various inflammatory and nutritional indexes in predicting pCR in LA-ESCC patients who received nICT"? Re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:691e98649e4948b0920f28c5","quotes":["Although this is not the first study to use inflammatory and nutritional ind... | [
"CLM:691e98649e4948b0920f28c5",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:135d8709a7b4cce47b24ca6b"
] | [] | [] | {"qa_id":"QA:336a82110bcf7b1b50e57f52","qa_group_id":"QAG:71d80899025a69a2f35c6d92","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Although this is not the first study to use inflammatory and nutri... |
QA:336b0ab1263b1609d13bcc23 | QAG:f4fc209bff2940b0fadee033 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The KEYNOTE-181 ( 19 ) and ESCORT ( 20 ) studies have shown that immunotherapy administered as a 2nd-line treatment improved the overall survival (OS) of patients with advanced esophageal cancer compared to chemotherapy"? Return the original wording with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e5e666d7410be9c9d45aa3d5","quotes":["The KEYNOTE-181 ( 19 ) and ESCORT ( 20 ) studies have shown that immunothera... | [
"CLM:e5e666d7410be9c9d45aa3d5",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:7a1df9901a19317b48ef2f20"
] | [] | [] | {"qa_id":"QA:336b0ab1263b1609d13bcc23","qa_group_id":"QAG:f4fc209bff2940b0fadee033","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The KEYNOTE-181 ( 19 ) and ESCORT ( 20 ) studies have shown that i... |
QA:371f54877d000d8b7559d677 | QAG:6fea6f231ec67d58d1994645 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In this retrospective study, we aims to evaluate the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy prior to surgery for patients with locally advanced ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated pr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6e75ae392d4766ab8c8c904b","quotes":["In this retrospective study, we aimed to evaluate the efficacy and safety of... | [
"CLM:6e75ae392d4766ab8c8c904b",
"CLM:271ef2ae6ac25da19ecda350"
] | [
"PMCID:PMC9251418"
] | [
"SPAN:a03f56e393e7fc8405ceeda7"
] | [] | [] | {"qa_id":"QA:371f54877d000d8b7559d677","qa_group_id":"QAG:6fea6f231ec67d58d1994645","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In this retrospective study, we aims to evaluate the efficacy and ... |
QA:3858854e84f76b7e80c06ae0 | QAG:23257bcdf0da540c7e2bdbb7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "25 These studies also showed that patients with advanced ESCC who received immunochemotherapy had significantly higher ORR than those who received chemotherapy alone"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:44e5cb6881d50593a1cfa8c4","quotes":["25 These studies also showed that patients with advanced ESCC who received i... | [
"CLM:44e5cb6881d50593a1cfa8c4",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:5afb8e01239e4d60191e7b11"
] | [] | [] | {"qa_id":"QA:3858854e84f76b7e80c06ae0","qa_group_id":"QAG:23257bcdf0da540c7e2bdbb7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"25 These studies also showed that patients with advanced ESCC who ... |
QA:395511bc8603dd4c8c4a19f7 | QAG:06d9c81e71944aac776e17c8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Although significant progress has been achieved in the treatment of esophageal cancer, its efficacy remains unsatisfactory"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e1e9c2b02bca82138901ddff","quotes":["Although significant progress has been achieved in the treatment of esophage... | [
"CLM:e1e9c2b02bca82138901ddff",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:4b891e38dabab9a8a7cdf8f0"
] | [] | [] | {"qa_id":"QA:395511bc8603dd4c8c4a19f7","qa_group_id":"QAG:06d9c81e71944aac776e17c8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Although significant progress has been achieved in the treatment o... |
QA:3a0fbad1187720576bf3ae70 | QAG:8b387593746270759c3e9d75 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "76%, which was higher than that of immunotherapy alone as the 2nd-line treatment for esophageal cancer (9.9–30%) ( 15 - 18 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d4fe455eb983bea698c468e1","quotes":["In this study, we found that the ORR of neoadjuvant immunotherapy combined w... | [
"CLM:d4fe455eb983bea698c468e1",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:01a74877669fbed2892730c0"
] | [] | [] | {"qa_id":"QA:3a0fbad1187720576bf3ae70","qa_group_id":"QAG:8b387593746270759c3e9d75","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"76%, which was higher than that of immunotherapy alone as the 2nd-... |
QA:3a8e39c83c477e0ca418a3cd | QAG:409bb3ed099d3fd100954421 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Beyond the subtype diagnostic and prognostic model, potential agents specific for subtype S2 were predicted which could open up new therapeutic options for improving the treatment efficacy of ESCC patients"? Return the original wording with paper, Claim, and Evidence S... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:960a0fbd3ede20b4c1359b9e","quotes":["Beyond the subtype diagnostic and prognostic model, potential agents specifi... | [
"CLM:960a0fbd3ede20b4c1359b9e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9599230"
] | [
"SPAN:cd06caee8fca58742fd8c2be"
] | [] | [] | {"qa_id":"QA:3a8e39c83c477e0ca418a3cd","qa_group_id":"QAG:409bb3ed099d3fd100954421","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Beyond the subtype diagnostic and prognostic model, potential agen... |
QA:3fbf62f1c026556d2bdcbfe9 | QAG:a37ad6fafba49d8f46a4c81c | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "reported that the initially unresectable locally advanced ESCC could be transformed into surgical candidates after receiving immunochemotherapy, and the conversion rate achieved 75% ( 8 )"? Return the original wording with paper, Claim, and Evidence Span references.
I... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:aee80904f313955121a1c9c6","quotes":["Further, Fan et al. reported that the initially unresectable locally advance... | [
"CLM:aee80904f313955121a1c9c6",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9326168"
] | [
"SPAN:4a8a635c0c71946aa9c47696"
] | [] | [] | {"qa_id":"QA:3fbf62f1c026556d2bdcbfe9","qa_group_id":"QAG:a37ad6fafba49d8f46a4c81c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"reported that the initially unresectable locally advanced ESCC cou... |
QA:3ff65560e5f2a083531592ca | QAG:f5965b0e6c7e96ee32c2caa1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients with advanced ESCC who received second or further-line treatment of anlotinib plus PD-1 blockade were grouped as cohort A (n=48), and those who received anlotinib monotherapy were grouped as cohort B (n=50)"? Return the original wording with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1706377140c679aaf90692f2","quotes":["Patients with advanced ESCC who received second or ... | [
"CLM:1706377140c679aaf90692f2",
"CLM:08a48a247c9286d56048a968",
"CLM:b95eb0dee0b66b44200ff790"
] | [
"PMCID:PMC9428701",
"PMCID:PMC9808083"
] | [
"SPAN:41a424d8ad80b9cfb678d3be",
"SPAN:0ac47b6461f852f718fc1878"
] | [
"ASC2:dc6a0667e31bc4ca5aca647a"
] | [
"HYP:DCH:29c4a571e77c6a8625deaf32"
] | {"qa_id":"QA:3ff65560e5f2a083531592ca","qa_group_id":"QAG:f5965b0e6c7e96ee32c2caa1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients with advanced ESCC who received second or further-line tr... |
QA:401c0293a5562bb75126e166 | QAG:92d1fa96084be2d88a1d04d9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "119 ESCC patients receiving combined treatment including anti-PD-1 antibody were enrolled in this study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, C... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:11a8bd68e85fd714329111fe","quotes":["119 ESCC patients receiving combined treatment incl... | [
"CLM:11a8bd68e85fd714329111fe",
"CLM:08a48a247c9286d56048a968",
"CLM:350aa98892765ca25e7ae951"
] | [
"PMCID:PMC8262036",
"PMCID:PMC8557514"
] | [
"SPAN:91fcf26088ed4609657329a5",
"SPAN:32049d0c34b0b26f3650b2f3"
] | [
"ASC2:f9b07037c11856dd062cf3e9"
] | [
"HYP:DCH:e785d9cdf3dc4bd151fd60e8"
] | {"qa_id":"QA:401c0293a5562bb75126e166","qa_group_id":"QAG:92d1fa96084be2d88a1d04d9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"119 ESCC patients receiving combined treatment including anti-PD-1... |
QA:421c976102717a6e57c594b6 | QAG:b85a6eebda9a8106c36ec382 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "From November 2019 to June 2021, 182 patients with ESCC were included at eight institutions in China and finally 155 patients completed the planned treatment courses"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0e54f44c909458e58a477a98","quotes":["From November 2019 to June 2021, 182 patients with ESCC were included at eig... | [
"CLM:0e54f44c909458e58a477a98",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9326168"
] | [
"SPAN:f3d5025463caeba529b1772b"
] | [] | [] | {"qa_id":"QA:421c976102717a6e57c594b6","qa_group_id":"QAG:b85a6eebda9a8106c36ec382","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"From November 2019 to June 2021, 182 patients with ESCC were inclu... |
QA:42b96a215bc22dd25b4681ed | QAG:917e36bbd80aad8d9eb9f975 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the published data from five multicenter RCTs with 1970 advanced ESCC patients, our pooled analysis revealed that PD-1 inhibitors as second-line therapy resulted in better OS and ORR in advanced ESCC patients than chemotherapy, especially prolonged OS in patients wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f3b93e2f44695ac4ff4330ec","quotes":["In the published data from five multicenter RCTs with 1970 advanced ESCC pat... | [
"CLM:f3b93e2f44695ac4ff4330ec",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:b6fcca4729328b49ea369c2b"
] | [] | [] | {"qa_id":"QA:42b96a215bc22dd25b4681ed","qa_group_id":"QAG:917e36bbd80aad8d9eb9f975","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the published data from five multicenter RCTs with 1970 advance... |
QA:430ea08a36856f9aa6dbc696 | QAG:b725429766ea04ca90b6f7d9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 98 consecutive patients with advanced ESCC were enrolled between January 2019 and February 2021. Of the 98 patients selected, including 69 (70.4%) males and 29 (29.6%) females"? Return the original wording with paper, Claim, and Evidence Span references.
In... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4bca23511c38a9a448f22a4f","quotes":["A total of 98 consecutive patients with advanced ESCC were enrolled between ... | [
"CLM:4bca23511c38a9a448f22a4f",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:1da5163c8ef83db5b408cfc3"
] | [] | [] | {"qa_id":"QA:430ea08a36856f9aa6dbc696","qa_group_id":"QAG:b725429766ea04ca90b6f7d9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 98 consecutive patients with advanced ESCC were enrolle... |
QA:44e251ff7368639160d88d97 | QAG:150ed1fdadb357734cb3eb66 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Figure 1 The flow diagram of selection of eligible LA-ESCC patients who received nICT followed by radical resection"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage w... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a831cd1fc9c8e7b2e4934857","quotes":["Figure 1 The flow diagram of selection of eligible LA-ESCC patients who rece... | [
"CLM:a831cd1fc9c8e7b2e4934857",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:f771858188ef61eb058530a2"
] | [] | [] | {"qa_id":"QA:44e251ff7368639160d88d97","qa_group_id":"QAG:150ed1fdadb357734cb3eb66","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Figure 1 The flow diagram of selection of eligible LA-ESCC patient... |
QA:44eadcfd35eab34b15965897 | QAG:d11feca43310e1cfca5c621b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 1970 trial participants from the five RCTs were included in this study, of which 987 received anti-PD-1 agent as a monotherapy for ESCC, while the other 983 received chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0bae1ded1329f81f0180dbc7","quotes":["A total of 1970 trial participants from the five RC... | [
"CLM:0bae1ded1329f81f0180dbc7",
"CLM:08a48a247c9286d56048a968",
"CLM:920eeff9e0fea211b0935088"
] | [
"PMCID:PMC8579527",
"PMCID:PMC9606329"
] | [
"SPAN:7dc09a9c47ed3fdf68375e12",
"SPAN:72099f17d508c1f9bf2adb05"
] | [
"ASC2:fdc940de06d153438bae0a3c"
] | [
"HYP:DCH:0a2dfc685db90739cacc0187"
] | {"qa_id":"QA:44eadcfd35eab34b15965897","qa_group_id":"QAG:d11feca43310e1cfca5c621b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 1970 trial participants from the five RCTs were include... |
QA:478063d41f2671e316d9a4d1 | QAG:1ccf803443b8640efe37d66f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Overall, PD‐1/PD‐L1 immunochemotherapy improved long‐term survival outcomes in patients with advanced ESCC compared with chemotherapy, independent of PD‐L1 TPS status but associated with CPS status"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:998d061fb7aca7b7dacc551f","quotes":["Overall, PD‐1/PD‐L1 immunochemotherapy significantly improved long‐term surv... | [
"CLM:998d061fb7aca7b7dacc551f",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:2cdf6371e922ef9cb13365e7"
] | [] | [] | {"qa_id":"QA:478063d41f2671e316d9a4d1","qa_group_id":"QAG:1ccf803443b8640efe37d66f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Overall, PD‐1/PD‐L1 immunochemotherapy improved long‐term survival... |
QA:47cac6a4fc5a30a6840ba800 | QAG:9689e7c8dacc28b6a8f2ea3a | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Our results highlight the predictive potential of spatial patterns of APCs in chemoradiotherapy combined with immunotherapy and reveal the underlying mechanism of APCs participating in chemoradiotherapy promoted antitumor immune response in ESCC"? Return the original w... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d78206eba5cb11f6616a8412","quotes":["Our results highlight the predictive potential of spatial patterns of APCs i... | [
"CLM:d78206eba5cb11f6616a8412",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC8761740"
] | [
"SPAN:aeafa97014484c2bf5bb35d4"
] | [] | [] | {"qa_id":"QA:47cac6a4fc5a30a6840ba800","qa_group_id":"QAG:9689e7c8dacc28b6a8f2ea3a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Our results highlight the predictive potential of spatial patterns... |
QA:4a081c51a7ca4b60eb636d30 | QAG:ca4068452c5b663080e156cf | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients received adebrelimab (administered intravenously at a dose of 20 mg per kg body weight every three weeks) on day 1 of a planned 21-day cycle, and two doses before surgery"? Return the original wording with paper, Claim, and Evidence Span references.
Integrate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f8134eaf03c1bd283f8bce63","quotes":["NATION-1907, a single-center, nonrandomized, phase 1b study, enrolled 30 pat... | [
"CLM:f8134eaf03c1bd283f8bce63",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC10427424"
] | [
"SPAN:2c8b61b227643f3de76cbd3d"
] | [] | [] | {"qa_id":"QA:4a081c51a7ca4b60eb636d30","qa_group_id":"QAG:ca4068452c5b663080e156cf","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients received adebrelimab (administered intravenously at a dos... |
QA:4b7da22d2a973042629a4a1c | QAG:a1cd49cf5b24450c480520d7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Table 5 The correlation of treatment response to immunotherapy and expression of CD73/PD-L1 in 38 ESCC patients who received pembrolizumab/nivolumab"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4c0180f3f01cfe4f56c46637","quotes":["Table 5 The correlation of treatment response to immunotherapy and expressio... | [
"CLM:4c0180f3f01cfe4f56c46637",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:6cb00b02e2818f82b57926e0"
] | [] | [] | {"qa_id":"QA:4b7da22d2a973042629a4a1c","qa_group_id":"QAG:a1cd49cf5b24450c480520d7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Table 5 The correlation of treatment response to immunotherapy and... |
QA:4db1185f65d222fbd9d506c9 | QAG:238c90a99d70c36a535907b4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The intratumor heterogeneity in ESCC, including genomic mutation and epigenomic aberrations ( 44 – 46 ) led to the heterogenetic immune characteristics under PD-1 blockade combined with chemoradiotherapy"? Return the original wording with paper, Claim, and Evidence Spa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f4259b784a51bc46d79da70f","quotes":["The intratumor heterogeneity in ESCC, including genomic mutation and epigeno... | [
"CLM:f4259b784a51bc46d79da70f",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC8761740"
] | [
"SPAN:0229ebebd38f375e87fcdd00"
] | [] | [] | {"qa_id":"QA:4db1185f65d222fbd9d506c9","qa_group_id":"QAG:238c90a99d70c36a535907b4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The intratumor heterogeneity in ESCC, including genomic mutation a... |
QA:4f05a643aa6bed2f687f2217 | QAG:11ed902cc9e9e613c115e2f1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Our study demonstrated that in patients with advanced ESCC treated with camrelizumab, high baseline NLR was associated with poor clinical outcomes regardless of PD‐L1 expression, suggesting NLR as a promising biomarker and that it could be supplementary to PD‐L1 expres... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:da80f1552ec58df1a1bf780e","quotes":["Our study demonstrated that in patients with advanced ESCC treated with camr... | [
"CLM:da80f1552ec58df1a1bf780e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9161342"
] | [
"SPAN:b16dc0eabfbd87caaf4a9774"
] | [] | [] | {"qa_id":"QA:4f05a643aa6bed2f687f2217","qa_group_id":"QAG:11ed902cc9e9e613c115e2f1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Our study demonstrated that in patients with advanced ESCC treated... |
QA:4f0ad0598a42fdd5e9e316ef | QAG:c4b1c00bb8eb12b251547568 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Low OTUD6B expression was associated with a poor prognosis of ESCC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7e94573353fa47d6303124d3","quotes":["Low OTUD6B expression is associated with a poor prognosis of ESCC patients."... | [
"CLM:7e94573353fa47d6303124d3",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:03336961f30841511cd2e338"
] | [] | [] | {"qa_id":"QA:4f0ad0598a42fdd5e9e316ef","qa_group_id":"QAG:c4b1c00bb8eb12b251547568","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Low OTUD6B expression was associated with a poor prognosis of ESCC... |
QA:4f21d2d1767e1dbebd04c99f | QAG:b3c9bb0b8826566af6cf4a96 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For example, Camrelizumab achieved the best PFS benefits in both the first-line and second-line treatments for patients with advanced ESCC, but may not convert to the best long-term OS benefit"? Return the original wording with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:33f543fa5be823435a040276","quotes":["For example, Camrelizumab achieved the best PFS benefits in both the first-l... | [
"CLM:33f543fa5be823435a040276",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9482734"
] | [
"SPAN:3eaf45569c2003947d7d2ad4"
] | [] | [] | {"qa_id":"QA:4f21d2d1767e1dbebd04c99f","qa_group_id":"QAG:b3c9bb0b8826566af6cf4a96","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For example, Camrelizumab achieved the best PFS benefits in both t... |
QA:4f605928cbccfa1e270d9625 | QAG:47f6757c1519e6588d116711 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For patients with advanced ESCC, cohort A led to significantly longer PFS (5.40 vs. 3.00 months, P<0.001) and higher DCR (71.7% vs. 47.9%, P=0.019) than cohort B. The ORR indicated no significant difference between cohort A (23.9%) and cohort B (10.4%) (P=0.082)"? Retu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1f6c0c04f1092da2733c0b22","quotes":["Results Data was collected until May 1, 2021, with ... | [
"CLM:1f6c0c04f1092da2733c0b22",
"CLM:08a48a247c9286d56048a968",
"CLM:279ac1ac7468c5fbc828a8ce",
"CLM:4a3471322cb61914835a391c"
] | [
"PMCID:PMC9428701",
"PMCID:PMC10261849",
"PMCID:PMC8579527"
] | [
"SPAN:8d6e0f43e4e8e7203c3c5b17",
"SPAN:2b581b6dc16736c1768d9339",
"SPAN:ba9785b6444fe128a8f3bf11"
] | [
"ASC2:a16a61c790ecf10e9a02779c",
"ASC2:e40fe99f05a8670b4a172f37"
] | [
"HYP:DCH:8d2c7bbb3817fe1eb6199fda"
] | {"qa_id":"QA:4f605928cbccfa1e270d9625","qa_group_id":"QAG:47f6757c1519e6588d116711","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For patients with advanced ESCC, cohort A led to significantly lon... |
QA:52412c722843906f2268ca6d | QAG:4337004badbaecf300003ffb | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In KEYNOTE-590, which investigated first-line therapy for advanced ESCC, pembrolizumab as one of the ICIs combined with chemotherapy improved overall survival (OS) in patients with advanced ESCC compared with placebo plus chemotherapy ( 10 )"? Return the original wordi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:41dc6ece7b843127c3efc468","quotes":["In KEYNOTE-590, which investigated first-line therapy for advanced ESCC, pem... | [
"CLM:41dc6ece7b843127c3efc468",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10089833"
] | [
"SPAN:62056a94a3d4ee771b68e876"
] | [] | [] | {"qa_id":"QA:52412c722843906f2268ca6d","qa_group_id":"QAG:4337004badbaecf300003ffb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In KEYNOTE-590, which investigated first-line therapy for advanced... |
QA:538aaf606a85049241164b7e | QAG:2a2291af2a9122fb5b4086f0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We have previously reported that local neutrophil infiltration in gastric cancer was associated with an immunosuppressive environment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact su... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e80866a1ee1fe83f80d53290","quotes":["We have previously reported that local neutrophil infiltration in gastric ca... | [
"CLM:e80866a1ee1fe83f80d53290",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:e0acf5e24844eda6b7887158"
] | [] | [] | {"qa_id":"QA:538aaf606a85049241164b7e","qa_group_id":"QAG:2a2291af2a9122fb5b4086f0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We have previously reported that local neutrophil infiltration in ... |
QA:53d477471ba2c1aefd0b9f71 | QAG:84cb8e1c39b2b794f37c3ee0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We found that knockdown of RAR α increased the protein level of OTUD6B in ESCC cells, while ectopic expression of RAR α decreased it (Figure 6K,L )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a0670f536aa005e4969c9220","quotes":["We found that knockdown of RAR α significantly increased the protein level o... | [
"CLM:a0670f536aa005e4969c9220",
"CLM:0c6c6d10a7936920ba93324f"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:481673354cb69ce44d49e9f7"
] | [] | [] | {"qa_id":"QA:53d477471ba2c1aefd0b9f71","qa_group_id":"QAG:84cb8e1c39b2b794f37c3ee0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We found that knockdown of RAR α increased the protein level of OT... |
QA:53f55b4faa0935fb5c86a34f | QAG:60e46721b706b26f3beb9fdc | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Despite significant inroads achieved in multidisciplinary treatment, the prognosis of patients with ESCC remains dismal ( 2 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:193750cd1bd5ce0618b1a4af","quotes":["Despite significant inroads achieved in multidisciplinary treatment, the pro... | [
"CLM:193750cd1bd5ce0618b1a4af",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:8049165379a214297eae7e1c"
] | [] | [] | {"qa_id":"QA:53f55b4faa0935fb5c86a34f","qa_group_id":"QAG:60e46721b706b26f3beb9fdc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Despite significant inroads achieved in multidisciplinary treatmen... |
QA:55730de05a61c7190c1698e0 | QAG:b84969127eef03ef39d7e7fe | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Sintilimab combined chemotherapy for ESCC prolonged OS and reduced the risk of death by 37.2%, according to the preliminary results of the Research ORIENT-15 ( NCT03748134 ) ( 13 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrat... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c558ea9b2162859e0c74cd29","quotes":["Sintilimab combined chemotherapy for ESCC significantly prolonged OS and red... | [
"CLM:c558ea9b2162859e0c74cd29",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9606329"
] | [
"SPAN:2b2229712462c8808866233c"
] | [] | [] | {"qa_id":"QA:55730de05a61c7190c1698e0","qa_group_id":"QAG:b84969127eef03ef39d7e7fe","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Sintilimab combined chemotherapy for ESCC prolonged OS and reduced... |
QA:5615e994912d5089847ceaed | QAG:afe579f93cf46c8d2f7c1ed4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Esophageal carcinoma was diagnosed in 604,100 patients and was associated with approximately 544,076 deaths worldwide in 2020, ranking seventh in incidence and sixth in mortality"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a8da5ef7dea1c9bd87413d49","quotes":["Esophageal carcinoma was diagnosed in 604,100 patients and was associated wi... | [
"CLM:a8da5ef7dea1c9bd87413d49",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9599230"
] | [
"SPAN:2ce9ea4bb6b1a9a5ce4feb5b"
] | [] | [] | {"qa_id":"QA:5615e994912d5089847ceaed","qa_group_id":"QAG:afe579f93cf46c8d2f7c1ed4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Esophageal carcinoma was diagnosed in 604,100 patients and was ass... |
QA:5627e4a207a8ac1ec5d67d25 | QAG:06bfb84d70868ad3b5fb440e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For ESCC patients who received chemotherapy alone, the pooled analysis showed that patients in the TP group had significantly higher 6- and 12-month OS rates than patients in the FP group"? Return the original wording with paper, Claim, and Evidence Span references.
I... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b08db3b9c03bae0070b6cb5e","quotes":["For ESCC patients who received chemotherapy alone, the pooled analysis showe... | [
"CLM:b08db3b9c03bae0070b6cb5e",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:27e838e445a62ff2ea89949a"
] | [] | [] | {"qa_id":"QA:5627e4a207a8ac1ec5d67d25","qa_group_id":"QAG:06bfb84d70868ad3b5fb440e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For ESCC patients who received chemotherapy alone, the pooled anal... |
QA:567f7794da10f0510bc93c76 | QAG:ebd64f7d49feaacc967f026e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "PFS rate in ESCC patients with low NLR at 6 weeks post treatment was higher than patients with high NLR (HR = 2.097, 95% CI 0.996–4.417, P = 0.027)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2b682449058e5e504b27af07","quotes":["PFS rate in ESCC patients with low NLR at 6 weeks post treatment was higher ... | [
"CLM:2b682449058e5e504b27af07",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:2b34bd708bce7c0d676005b3"
] | [] | [] | {"qa_id":"QA:567f7794da10f0510bc93c76","qa_group_id":"QAG:ebd64f7d49feaacc967f026e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"PFS rate in ESCC patients with low NLR at 6 weeks post treatment w... |
QA:5722506c75a9e262277efb98 | QAG:e3225de8ff09a95d854841bb | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In our retrospective study, the second or further-line treatment of anlotinib monotherapy in advanced ESCC led to a median PFS of 3.00 months and a DCR of 47.9%, In contrast, the combination treatment showed a median PFS of 5.40 months and a DCR of 71.7%, presenting an... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:eaa4917da8548e28b4a6d0b2","quotes":["In our retrospective study, the second or further-line treatment of anlotini... | [
"CLM:eaa4917da8548e28b4a6d0b2",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:c35cf6ebaff65c154748ff4b"
] | [] | [] | {"qa_id":"QA:5722506c75a9e262277efb98","qa_group_id":"QAG:e3225de8ff09a95d854841bb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In our retrospective study, the second or further-line treatment o... |
QA:57cbccf065ab1fbaa0a020f8 | QAG:12212c93dc680d36399c6b64 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "(IV) had previously received radiotherapy or systemic anti-cancer therapy; (V) suffered from active tuberculosis; (VI) had an esophageal fistula before treatment; and/or (VII) had distant metastases"? Return the original wording with paper, Claim, and Evidence Span ref... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cce5e910856ef1eda5c70176","quotes":["Patients were excluded if they met any of the following criteria: (I) had no... | [
"CLM:cce5e910856ef1eda5c70176",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:5b2448bc02f2ad68e37c2102"
] | [] | [] | {"qa_id":"QA:57cbccf065ab1fbaa0a020f8","qa_group_id":"QAG:12212c93dc680d36399c6b64","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"(IV) had previously received radiotherapy or systemic anti-cancer ... |
QA:585b9fcadd3450c76e40a3f4 | QAG:9d4a994f0cbdc0f4d2f71859 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "3%, pathological downstaging was achieved in 74.0% of patients, and 1-year DFS rate was 95.2%"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8c2fdb736d52e0efbe3c3585","quotes":["In the present study, neoadjuvant sintilimab plus chemotherapy in patients w... | [
"CLM:8c2fdb736d52e0efbe3c3585",
"CLM:2a0dc33e26036765ea69bb10"
] | [
"PMCID:PMC9098952"
] | [
"SPAN:2e842f6306c6c5e676c93097"
] | [] | [] | {"qa_id":"QA:585b9fcadd3450c76e40a3f4","qa_group_id":"QAG:9d4a994f0cbdc0f4d2f71859","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"3%, pathological downstaging was achieved in 74.0% of patients, an... |
QA:592538c39a1a099a51a46a62 | QAG:69d0de6cf684532607d7b400 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 236 patients (mean age, 67 years) who had undergone esophagectomy with reconstruction for ESCC were enrolled in this study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact su... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ba5e33dd91ba56caf845ed53","quotes":["A total of 236 patients (mean age, 67 years) who had undergone esophagectomy... | [
"CLM:ba5e33dd91ba56caf845ed53",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:f8a0c93b4a672733f3c93a19"
] | [] | [] | {"qa_id":"QA:592538c39a1a099a51a46a62","qa_group_id":"QAG:69d0de6cf684532607d7b400","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 236 patients (mean age, 67 years) who had undergone eso... |
QA:59dbafafdc46f4dee07b78d9 | QAG:9fec48a46238afd3d7457fdd | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "All RCTs assessing first-line treatments for esophageal cancer were included in this systematic review, without any restrictions on publication date, location or language"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provena... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:df5d0625885e24a69797051a","quotes":["All RCTs assessing first-line treatments for esophageal cancer were included... | [
"CLM:df5d0625885e24a69797051a",
"CLM:0313c682e9e59efb742366b7"
] | [
"PMCID:PMC10714592"
] | [
"SPAN:20bdccf307cd1fc58cfed367"
] | [] | [] | {"qa_id":"QA:59dbafafdc46f4dee07b78d9","qa_group_id":"QAG:9fec48a46238afd3d7457fdd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"All RCTs assessing first-line treatments for esophageal cancer wer... |
QA:59eb01006d445845e2959757 | QAG:76efa6f689fbca5d8f09762f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A meta-analysis indicated that neoadjuvant immunochemoradiotherapy led to a higher pCR rate compared to immunochemotherapy for ESCC, and increasing the cycles of ICI did not appear to improve the pCR rate ( 166 )"? Return the original wording with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5b190b79f1ccce61b8c25495","quotes":["A meta-analysis indicated that neoadjuvant immunochemoradiotherapy led to a ... | [
"CLM:5b190b79f1ccce61b8c25495",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:c517accfbe3d4da781a6d33c"
] | [] | [] | {"qa_id":"QA:59eb01006d445845e2959757","qa_group_id":"QAG:76efa6f689fbca5d8f09762f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A meta-analysis indicated that neoadjuvant immunochemoradiotherapy... |
QA:5a95ab4d3a4878f12c7c223c | QAG:0042829a2f67952e0ac04c42 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Hence, this study aims to evaluate the feasibility, safety, and effectiveness of conversion surgery following induction immunochemotherapy (iIC) for initially unresectable ESCC in a real-world scenario"? Return the original wording with paper, Claim, and Evidence Span ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1386fb63ba9c80fd187d8546","quotes":["Hence, this study aimed to evaluate the feasibility, safety, and effectivene... | [
"CLM:1386fb63ba9c80fd187d8546",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC9326168"
] | [
"SPAN:e492ea8ac7a9455ec368f459"
] | [] | [] | {"qa_id":"QA:5a95ab4d3a4878f12c7c223c","qa_group_id":"QAG:0042829a2f67952e0ac04c42","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Hence, this study aims to evaluate the feasibility, safety, and ef... |
QA:5b36e31cffe7145a6c55541c | QAG:565fe4a8663771746f66e239 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We enrolled 38 patients who received pembrolizumab or nivolumab as second-line or later-line treatment for ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bb1b1feb55ecad7831b0e41c","quotes":["We enrolled 38 patients who received pembrolizumab or nivolumab as second-li... | [
"CLM:bb1b1feb55ecad7831b0e41c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:c01a3ab2662e159191ff66e1"
] | [] | [] | {"qa_id":"QA:5b36e31cffe7145a6c55541c","qa_group_id":"QAG:565fe4a8663771746f66e239","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We enrolled 38 patients who received pembrolizumab or nivolumab as... |
QA:5c9063eea4fc67e6f4860d71 | QAG:60cd18011f9be12ed81a73b0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Materials and Methods In this multi-center, real-world study ( NCT04822103 ), patients who had unresectable ESCC disease were enrolled across eight medical centers in China"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prove... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2bb5ccb7ef7afe098c1c8ea2","quotes":["Materials and Methods In this multi-center, real-world study ( NCT04822103 )... | [
"CLM:2bb5ccb7ef7afe098c1c8ea2",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9326168"
] | [
"SPAN:a6cfe8d51d56e1a715712898"
] | [] | [] | {"qa_id":"QA:5c9063eea4fc67e6f4860d71","qa_group_id":"QAG:60cd18011f9be12ed81a73b0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Materials and Methods In this multi-center, real-world study ( NCT... |
QA:5e034dadf1c32539b64e8392 | QAG:24455713841eab112019554e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We confirmed that in two ESCC cell lines, KYSE150 and KYSE180 cells, β ‐TrCP protein level was also increased by OTUD6B ectopic expression but β ‐TrCP mRNA level was not influenced (Figure 1K,L )"? Return the original wording with paper, Claim, and Evidence Span refere... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:35fc6a415a19766d8f8598f0","quotes":["We confirmed that in two ESCC cell lines, KYSE150 and KYSE180 cells, β ‐TrCP... | [
"CLM:35fc6a415a19766d8f8598f0",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:43d5a5c9844b1e3ad0c84219"
] | [] | [] | {"qa_id":"QA:5e034dadf1c32539b64e8392","qa_group_id":"QAG:24455713841eab112019554e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We confirmed that in two ESCC cell lines, KYSE150 and KYSE180 cell... |
QA:5e5e2224dc1794765f928279 | QAG:f2b19486e3c61eddce89c6b5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "patients with advanced ESCC received paclitaxel plus platinum"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; assess... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:67b613ba9f5862eb4cbf04bd","quotes":["In a study by Kim J.Y., patients with advanced ESCC were treated with paclit... | [
"CLM:67b613ba9f5862eb4cbf04bd",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10714592"
] | [
"SPAN:bcfbe1a973ebc89db98ab7c8"
] | [] | [] | {"qa_id":"QA:5e5e2224dc1794765f928279","qa_group_id":"QAG:f2b19486e3c61eddce89c6b5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"patients with advanced ESCC received paclitaxel plus platinum\"? R... |
QA:5e6f457c45881c8a09fa6a84 | QAG:6f46a91a40b141735c79171f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A multicenter, single-arm, phase II trial aims to evaluate the safety and efficacy of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced ESCC had been reported ( 27 )"? Return the original wording with paper, Claim, and Evidence Span references... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:412a13514bc34f01f242c89c","quotes":["A multicenter, single-arm, phase II trial aimed to evaluate the safety and e... | [
"CLM:412a13514bc34f01f242c89c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9585292"
] | [
"SPAN:5695d1dcb4ad510959d4cb6c"
] | [] | [] | {"qa_id":"QA:5e6f457c45881c8a09fa6a84","qa_group_id":"QAG:6f46a91a40b141735c79171f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A multicenter, single-arm, phase II trial aims to evaluate the saf... |
QA:5f8f5bd4e19b624f5ba7da47 | QAG:c6502d8c09e54aba83c2ca6d | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Background In the randomized phase III KEYNOTE-181 study, pembrolizumab prolonged overall survival (OS) compared with chemotherapy as second-line therapy in patients with advanced esophageal cancer and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:580c824bceb1b0aeaa9fd109","quotes":["Background In the randomized phase III KEYNOTE-181 ... | [
"CLM:580c824bceb1b0aeaa9fd109",
"CLM:08a48a247c9286d56048a968",
"CLM:425974891808dce8b8d00e8e"
] | [
"PMCID:PMC8764510",
"PMCID:PMC8393769"
] | [
"SPAN:71063e623dc78ac3a46296fa",
"SPAN:a3b22a554f92238d551cc368"
] | [
"ASC2:71f149421be2a1a205289b82"
] | [
"HYP:DCH:26430c1e880d586b70734fa2"
] | {"qa_id":"QA:5f8f5bd4e19b624f5ba7da47","qa_group_id":"QAG:c6502d8c09e54aba83c2ca6d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Background In the randomized phase III KEYNOTE-181 study, pembroli... |
QA:5faa4302e31ce4e7f257c0cf | QAG:34d7e9dc5cf0e3be77a6a123 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with conventional chemotherapy, second-line PD-1 inhibitors improved the OS (hazard ratio [HR] = 0.73, 95% confidence interval [CI]: 0.66–0.81; P < 0.001) and ORR (relative risk [RR] = 1.89, 95% CI: 1.16–3.05; P = 0.01) of advanced ESCC patients, especially si... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4a3471322cb61914835a391c","quotes":["Compared with conventional... | [
"CLM:4a3471322cb61914835a391c",
"CLM:08a48a247c9286d56048a968",
"CLM:1f6c0c04f1092da2733c0b22",
"CLM:279ac1ac7468c5fbc828a8ce"
] | [
"PMCID:PMC8579527",
"PMCID:PMC9428701",
"PMCID:PMC10261849"
] | [
"SPAN:2b581b6dc16736c1768d9339",
"SPAN:8d6e0f43e4e8e7203c3c5b17",
"SPAN:ba9785b6444fe128a8f3bf11"
] | [
"ASC2:e40fe99f05a8670b4a172f37",
"ASC2:a16a61c790ecf10e9a02779c"
] | [
"HYP:DCH:15c01c6878150af640b4c240",
"HYP:DCH:16a33beaaa2b2609fcdeb029"
] | {"qa_id":"QA:5faa4302e31ce4e7f257c0cf","qa_group_id":"QAG:34d7e9dc5cf0e3be77a6a123","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with conventional chemotherapy, second-line PD-1 inhibito... |
QA:602c40e6a30ffe566f2ac516 | QAG:22d7f9ed7af0515cee60eb3c | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the published data from five multicenter RCTs with 1970 advanced ESCC patients, our pooled analysis revealed that PD-1 inhibitors as second-line therapy resulted in better OS and ORR in advanced ESCC patients than chemotherapy, especially significantly prolonged OS ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:db780766332f491f65416d43","quotes":["In the published data from five multicenter RCTs with 1970 advanced ESCC pat... | [
"CLM:db780766332f491f65416d43",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:b6fcca4729328b49ea369c2b"
] | [] | [] | {"qa_id":"QA:602c40e6a30ffe566f2ac516","qa_group_id":"QAG:22d7f9ed7af0515cee60eb3c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the published data from five multicenter RCTs with 1970 advance... |
QA:605e26cd53136e9be7b6b906 | QAG:ad7f861792712b0492a65b1a | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For example, a randomized, open-label, phase 3 study named ESCORT found that patients with advanced or metastatic esophageal squamous cell carcinoma who had previously failed first-line chemotherapy and received camrelizumab alone significantly extended survival when c... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:94b4d6a86af0492ae3e726d1","quotes":["For example, a randomized, open-label, phase 3 study named ESCORT found that... | [
"CLM:94b4d6a86af0492ae3e726d1",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:07164f516531d274511f3134"
] | [] | [] | {"qa_id":"QA:605e26cd53136e9be7b6b906","qa_group_id":"QAG:ad7f861792712b0492a65b1a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For example, a randomized, open-label, phase 3 study named ESCORT ... |
QA:60dd37613ad8da5dfecff063 | QAG:a9373ac6d6367545d3715594 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 1970 trial participants from the five RCTs were included in this study, of which 987 received anti-PD-1 agent as a monotherapy for ESCC, while the other 983 received chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c2b3d8817d5975fb6dca3ff0","quotes":["A total of 1970 trial participants from the five RCTs were included in this ... | [
"CLM:c2b3d8817d5975fb6dca3ff0",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:7dc09a9c47ed3fdf68375e12"
] | [] | [] | {"qa_id":"QA:60dd37613ad8da5dfecff063","qa_group_id":"QAG:a9373ac6d6367545d3715594","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 1970 trial participants from the five RCTs were include... |
QA:61b44a5d431e0f6e9447b4ec | QAG:cb50a0d350df24fe6b3b4f7d | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Overall, a high enrichment score of the TREM2 + TAMs gene signature predicted poor OS and PFS and was associated with potential immunotherapy modulation"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ee7bf58ff9f632bd3556d9eb","quotes":["In addition, we collected 10 samples from ESCC patients treated with immunot... | [
"CLM:ee7bf58ff9f632bd3556d9eb",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:2cf2acf2640f64a604aaae7c"
] | [] | [] | {"qa_id":"QA:61b44a5d431e0f6e9447b4ec","qa_group_id":"QAG:cb50a0d350df24fe6b3b4f7d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Overall, a high enrichment score of the TREM2 + TAMs gene signatur... |
QA:61cc84479e9e0e79575fea30 | QAG:e42323edb3819fb29ffd87fd | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "4 Our study demonstrated that compared with the chemotherapy alone, PD‐1/PD‐L1‐based immunochemotherapy improved survival outcomes in patients with advanced ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:614bbf5ba4d913d6e665b5f0","quotes":["4 Our study demonstrated that compared with the chemotherapy alone, PD‐1/PD‐... | [
"CLM:614bbf5ba4d913d6e665b5f0",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:6d28e0961abbf5ecd75c2233"
] | [] | [] | {"qa_id":"QA:61cc84479e9e0e79575fea30","qa_group_id":"QAG:e42323edb3819fb29ffd87fd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"4 Our study demonstrated that compared with the chemotherapy alone... |
QA:6224641838ce1e6092754810 | QAG:483ac151ba7ccb8362287283 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "6 months for ESCC patients who received pembrolizumab plus FP chemotherapy and 9.8 months in the placebo plus chemotherapy group (P=0.0006)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ex... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:063792c6211f8080df71e9da","quotes":["In the KEYNOTE-590 trial ( 10 ), results showed that the median OS was 12.6 ... | [
"CLM:063792c6211f8080df71e9da",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:7ef7f13dd17a0e96a54ffbc4"
] | [] | [] | {"qa_id":"QA:6224641838ce1e6092754810","qa_group_id":"QAG:483ac151ba7ccb8362287283","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"6 months for ESCC patients who received pembrolizumab plus FP chem... |
QA:62354b43fbcb37fc249d7e40 | QAG:bd1bb86ac0d0727b16c53ff3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "To validate the performance of the established model in a clinical setting, we collected 36 Chinese ESCC patients who had received anti-PD-1/PD-L1 therapy in combination with chemotherapy between January 2018 and December 2020 from The First Affiliated Hospital, School... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:97b4aece1043a2636dc2d641","quotes":["To validate the performance of the established model in a clinical setting, ... | [
"CLM:97b4aece1043a2636dc2d641",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9599230"
] | [
"SPAN:95890cfd8c9840ed27462ff4"
] | [] | [] | {"qa_id":"QA:62354b43fbcb37fc249d7e40","qa_group_id":"QAG:bd1bb86ac0d0727b16c53ff3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"To validate the performance of the established model in a clinical... |
QA:641cbebb379da51ec6f0e808 | QAG:0ef596793b5f87438162f9a2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Nevertheless, combining the finding of closer distribution of APCs around tumor cells during combination, we highlighted that tumor tropism of APCs promoted by increased release of tumor neoantigens was one of the most important antitumor mechanisms in this combination... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:da2da2d0707cff5524f74e1e","quotes":["Nevertheless, combining the finding of closer distribution of APCs around tu... | [
"CLM:da2da2d0707cff5524f74e1e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8761740"
] | [
"SPAN:19ab6fd057ff8e1be6e50ee1"
] | [] | [] | {"qa_id":"QA:641cbebb379da51ec6f0e808","qa_group_id":"QAG:0ef596793b5f87438162f9a2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Nevertheless, combining the finding of closer distribution of APCs... |
QA:6632c50eb3d9f752cf66c0cf | QAG:e0253d0cae63b14a6710d1a5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients with resectable locally advanced ESCC who received neoadjuvant sintilimab in combination with chemotherapy followed by surgery between July 2019 to August 2021 were identified from the database of Thoracic Surgery, The Fourth Hospital of Hebei Medical Universi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:21b4cb1e3acc2b3199030d15","quotes":["Patients with resectable locally advanced ESCC who received neoadjuvant sint... | [
"CLM:21b4cb1e3acc2b3199030d15",
"CLM:53f595b2e5be60ea885f52ca"
] | [
"PMCID:PMC9098952"
] | [
"SPAN:f7cd00e2cb99133ae5c6fa72"
] | [] | [] | {"qa_id":"QA:6632c50eb3d9f752cf66c0cf","qa_group_id":"QAG:e0253d0cae63b14a6710d1a5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients with resectable locally advanced ESCC who received neoadj... |
QA:66685a5b029cb02a4bced85e | QAG:80698c30e47854a072303e54 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In cases where GC-TLSs were frequently observed, the clinical efficacy of NAC was high, and long-term prognosis was achieved even in locally advanced esophageal cancer such as clinical stages 3 and 4. This indicates that the change in the local immune environment of es... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:91793f61fe1beb87412abb8e","quotes":["In cases where GC-TLSs were frequently observed, the clinical efficacy of NA... | [
"CLM:91793f61fe1beb87412abb8e",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:445fd151835f07974c8c423d"
] | [] | [] | {"qa_id":"QA:66685a5b029cb02a4bced85e","qa_group_id":"QAG:80698c30e47854a072303e54","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In cases where GC-TLSs were frequently observed, the clinical effi... |
QA:694deb16db82da8e779ca5a1 | QAG:49ec06cf30f45ae7cd2585ed | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Unfortunately, PLR, MLR and SII was not associated with the response to the anti-PD-1 treatment in ESCC patients, as a result of which, it was assuming that NLR was a vital factor reflecting the system inflammation response after anti-PD-1 therapy"? Return the original... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4e2e5f5f2097cff48f0d0a1c","quotes":["Unfortunately, PLR, MLR and SII were not associated with the response to the... | [
"CLM:4e2e5f5f2097cff48f0d0a1c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:ce8e51e4ff016c9fb168eee6"
] | [] | [] | {"qa_id":"QA:694deb16db82da8e779ca5a1","qa_group_id":"QAG:49ec06cf30f45ae7cd2585ed","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Unfortunately, PLR, MLR and SII was not associated with the respon... |
QA:69eefdd69abf52599b0596c0 | QAG:e920da34cf4fe550c15220ad | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "TREM2 + TAMs from ESCC exhibited a consistent expression pattern and identical signature genes ( TREM2, SPP1, APOE, C1QC, C1QB , and C1QA ) with melanoma cells, suggesting that TREM2 + TAMs was associated with immunotherapy resistance in ESCC"? Return the original word... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:70d7049ab2e380e56d84f70b","quotes":["TREM2 + TAMs from ESCC exhibited a consistent expression pattern and identic... | [
"CLM:70d7049ab2e380e56d84f70b",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:b6243de708e6cac0a6e25895"
] | [] | [] | {"qa_id":"QA:69eefdd69abf52599b0596c0","qa_group_id":"QAG:e920da34cf4fe550c15220ad","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"TREM2 + TAMs from ESCC exhibited a consistent expression pattern a... |
QA:6a3d778bbc449f9c72ca497e | QAG:41d287e024fef08f98841fa7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Worldwide, the number of new cases of esophageal cancer (EC) achieved 572,000, and the number of deaths was 509,000 in 2018 ( 1 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c1f7ddabd95f4c74d8f44c7c","quotes":["Worldwide, the number of new cases of esophageal cancer (EC) reached 572,000... | [
"CLM:c1f7ddabd95f4c74d8f44c7c",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9606329"
] | [
"SPAN:94e1f2a7556f3e345ddca3ba"
] | [] | [] | {"qa_id":"QA:6a3d778bbc449f9c72ca497e","qa_group_id":"QAG:41d287e024fef08f98841fa7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Worldwide, the number of new cases of esophageal cancer (EC) achie... |
QA:6a8a9866a7d2976086e0a843 | QAG:5c12f0c1c9c0b771a3a9387a | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "14–18 However, the exact mechanisms of these indexes for pCR in ESCC received nICT remain unclear"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:863604d9fbfebc251641392e","quotes":["14–18 However, the exact mechanisms of these indexes for pCR in ESCC receive... | [
"CLM:863604d9fbfebc251641392e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:fb8663b21e3315c82343a7a9"
] | [] | [] | {"qa_id":"QA:6a8a9866a7d2976086e0a843","qa_group_id":"QAG:5c12f0c1c9c0b771a3a9387a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"14–18 However, the exact mechanisms of these indexes for pCR in ES... |
QA:6b2da78dd0b7432bec4ff564 | QAG:095d43d2f13008c16061bfcc | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Currently, immunotherapy has led to great improvements in first- and second-line settings in advanced-stage ESCC 11 , 12 , but is yet to be approved in the preoperative setting"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:aa247c3ca4d2f98d92fdf766","quotes":["Currently, immunotherapy has led to great improvements in first- and second-... | [
"CLM:aa247c3ca4d2f98d92fdf766",
"CLM:271ef2ae6ac25da19ecda350"
] | [
"PMCID:PMC10427424"
] | [
"SPAN:d201696adb966d3b6c0b1cad"
] | [] | [] | {"qa_id":"QA:6b2da78dd0b7432bec4ff564","qa_group_id":"QAG:095d43d2f13008c16061bfcc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Currently, immunotherapy has led to great improvements in first- a... |
QA:6b8dac42a0f6cedca9262a91 | QAG:5a93f63bc10d409e40cc736b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "8 , 27 All ESCC patients who received camrelizumab monotherapy enrolled in these two clinical trials at National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences were consecutively included in the analysis"? Return the original wording with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8e6404bcb532dac01527540c","quotes":["8 , 27 All ESCC patients who received camrelizumab monotherapy enrolled in t... | [
"CLM:8e6404bcb532dac01527540c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9161342"
] | [
"SPAN:754d70da0f64e64027cbcf2c"
] | [] | [] | {"qa_id":"QA:6b8dac42a0f6cedca9262a91","qa_group_id":"QAG:5a93f63bc10d409e40cc736b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"8 , 27 All ESCC patients who received camrelizumab monotherapy enr... |
QA:6bebca1610bc7dcf79c2d501 | QAG:c475f203203e37a51566d8d0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Our meta-analysis showed that ICIs improved OS and ORR in the second-line treatment of advanced ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c5c20e960224235c936902f9","quotes":["Our meta-analysis showed that ICIs significantly improved OS and ORR in the ... | [
"CLM:c5c20e960224235c936902f9",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10089833"
] | [
"SPAN:a02f77a2a9f382fdcb247ea0"
] | [] | [] | {"qa_id":"QA:6bebca1610bc7dcf79c2d501","qa_group_id":"QAG:c475f203203e37a51566d8d0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Our meta-analysis showed that ICIs improved OS and ORR in the seco... |
QA:6d74036511dd930d631fbde3 | QAG:acf7c6b432196c6b2687d1f1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The medical trials that met the following inclusion criteria were included (I) the study within the article showed that advanced ESCC is generally not suitable for surgical treatment; (II) ICIs for clinical trials had been approved by the Food and Drug Administration (... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dabeb9fcabe93246ef151d81","quotes":["The medical trials that met the following inclusion criteria were included: ... | [
"CLM:dabeb9fcabe93246ef151d81",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10089833"
] | [
"SPAN:028d238f99d39e2fa38b9136"
] | [] | [] | {"qa_id":"QA:6d74036511dd930d631fbde3","qa_group_id":"QAG:acf7c6b432196c6b2687d1f1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The medical trials that met the following inclusion criteria were ... |
QA:6df72dc703b080934f80cab3 | QAG:a37b5c452336c69f548a5a16 | provenance_qa | paper_evidence_availability | provenance_qa | G023 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC11796932? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC11796932","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC11796932"
] | [] | [] | [] | {"qa_id":"QA:6df72dc703b080934f80cab3","qa_group_id":"QAG:a37b5c452336c69f548a5a16","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G023","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1179693... |
QA:6dfb5871b9882edb48181be0 | QAG:d0dc87fbcaf8328d05ec32aa | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Results: We identify two molecular subtypes of ESCC (S1 and S2) that was associated with distinct immune-related pathways, tumor microenvironment and clinical outcomes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ec194ed57b9ea5e3664679f8","quotes":["Results: We identify two molecular subtypes of ESCC (S1 and S2) that are ass... | [
"CLM:ec194ed57b9ea5e3664679f8",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9599230"
] | [
"SPAN:854ea255b6826a786db5663a"
] | [] | [] | {"qa_id":"QA:6dfb5871b9882edb48181be0","qa_group_id":"QAG:d0dc87fbcaf8328d05ec32aa","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Results: We identify two molecular subtypes of ESCC (S1 and S2) th... |
QA:6e657428e572d859aed8a385 | QAG:32ddba728d27c4bc7169be66 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Results Of the 285 enrolled LA-ESCC patients received nICT followed by radical resection, 84 (29.5%) patients achieved pCR"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3254f342b41acbd9410aad0d","quotes":["Results Of the 285 enrolled LA-ESCC patients received nICT followed by radic... | [
"CLM:3254f342b41acbd9410aad0d",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:538b7a39ad4c3d2be43400f4"
] | [] | [] | {"qa_id":"QA:6e657428e572d859aed8a385","qa_group_id":"QAG:32ddba728d27c4bc7169be66","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Results Of the 285 enrolled LA-ESCC patients received nICT followe... |
QA:6f8f4c67e5c10deb9f1086e0 | QAG:b29051dc71ebcb5e21e0de15 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Nevertheless, combining the finding of closer distribution of APCs around tumor cells during combination, we highlighted that tumor tropism of APCs promoted by increased release of tumor neoantigens was one of the most important antitumor mechanisms in this combination... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d42cead28cc660f84c1be909","quotes":["Nevertheless, combining the finding of closer distribution of APCs around tu... | [
"CLM:d42cead28cc660f84c1be909",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8761740"
] | [
"SPAN:19ab6fd057ff8e1be6e50ee1"
] | [] | [] | {"qa_id":"QA:6f8f4c67e5c10deb9f1086e0","qa_group_id":"QAG:b29051dc71ebcb5e21e0de15","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Nevertheless, combining the finding of closer distribution of APCs... |
QA:70d65bc2e55029c403f258e9 | QAG:2bfdd721b2b9cd7378d182b3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The randomized phase III trials (ATTRACTION-3, ESCORT, KEYNOTE-181 and ORIENT-2) have shown that PD-1 blockades was associated with a better OS than chemotherapy as second-line therapy for advanced ESCC ( 15 – 18 )"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f6e5a781e5ed0284e92a62a1","quotes":["The randomized phase III trials (ATTRACTION-3, ESCORT, KEYNOTE-181 and ORIEN... | [
"CLM:f6e5a781e5ed0284e92a62a1",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:3eda9e6e3e1e14f99708061d"
] | [] | [] | {"qa_id":"QA:70d65bc2e55029c403f258e9","qa_group_id":"QAG:2bfdd721b2b9cd7378d182b3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The randomized phase III trials (ATTRACTION-3, ESCORT, KEYNOTE-181... |
QA:7261c11e537fad3558f4675b | QAG:092e8640a055c8271950aec5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The above analysis demonstrated that high NLR at 6 weeks post treatment but not at baseline or at 3 weeks was related to shorter PFS in ESCC patients and NLR was increased in ESCC patients when compared with tumor-free people, thus we estimated whether the change of NL... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:98ac07bc8f482cb31f6a295f","quotes":["The above analysis demonstrated that high NLR at 6 weeks post treatment but ... | [
"CLM:98ac07bc8f482cb31f6a295f",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:afff6fdbc868c4f8223cdb85"
] | [] | [] | {"qa_id":"QA:7261c11e537fad3558f4675b","qa_group_id":"QAG:092e8640a055c8271950aec5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The above analysis demonstrated that high NLR at 6 weeks post trea... |
QA:73071deee5af14e53bc84686 | QAG:866e51b479660acef3caa6bc | provenance_qa | paper_evidence_availability | provenance_qa | G023 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10992948? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10992948","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10992948"
] | [] | [] | [] | {"qa_id":"QA:73071deee5af14e53bc84686","qa_group_id":"QAG:866e51b479660acef3caa6bc","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G023","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1099294... |
QA:7408da977bc1d56e94d6cdc9 | QAG:beb076afad7d062111b162a8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "reported that TLS-rich was a prognostic factor for superficial esophageal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f73015a995075984fd7fb5da","quotes":["Zhao et al. reported that TLS-rich is a prognostic factor for superficial es... | [
"CLM:f73015a995075984fd7fb5da",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:6994ce04fff81af2aa652ecf"
] | [] | [] | {"qa_id":"QA:7408da977bc1d56e94d6cdc9","qa_group_id":"QAG:beb076afad7d062111b162a8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"reported that TLS-rich was a prognostic factor for superficial eso... |
QA:778b900906057c6cfb9dccd3 | QAG:d9cb4f85adb143da50d717b5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Furthermore, multiplex immunofluorescence successfully visualized TREM2 + TAMs in ESCC tissues, and a high level of infiltrating TREM2 + TAMs was correlated with poorer overall survival"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:09bc83b3d74bfe16ec396f98","quotes":["Furthermore, multiplex immunofluorescence successfully visualized TREM2 + TA... | [
"CLM:09bc83b3d74bfe16ec396f98",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:d5e63aa916547859f577505b"
] | [] | [] | {"qa_id":"QA:778b900906057c6cfb9dccd3","qa_group_id":"QAG:d9cb4f85adb143da50d717b5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Furthermore, multiplex immunofluorescence successfully visualized ... |
QA:78d522340af8a4746d56f648 | QAG:c8b73301c485b22391d24de2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In ESCC tumor samples, OTUD6B expression was correlated with β ‐TrCP and its lower expression associates with a poor prognosis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1f1e7ae9ac05e0d3610a1870","quotes":["In ESCC tumor samples, OTUD6B expression is positively correlated with β ‐Tr... | [
"CLM:1f1e7ae9ac05e0d3610a1870",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:3de1513f9c8e631f46736d4b"
] | [] | [] | {"qa_id":"QA:78d522340af8a4746d56f648","qa_group_id":"QAG:c8b73301c485b22391d24de2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In ESCC tumor samples, OTUD6B expression was correlated with β ‐Tr... |
QA:7912f01e227175f9c59237e5 | QAG:44e6599b63c078f7e9aef19d | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Our meta‐analysis showed that immunochemotherapy decreased the overall risk of death by 32% (HR = 0.68, 95% CI 0.61–0.75) and the risk of disease progression by 38% (HR = 0.62, 95% CI 0.55, 0.70) in patients with advanced ESCC compared with chemotherapy alone"? Return ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d90125ba437bd205bdbb1219","quotes":["Our meta‐analysis showed that immunochemotherapy reduced the overall risk of... | [
"CLM:d90125ba437bd205bdbb1219",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:36226dd94b34cfa69ca6d1e8"
] | [] | [] | {"qa_id":"QA:7912f01e227175f9c59237e5","qa_group_id":"QAG:44e6599b63c078f7e9aef19d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Our meta‐analysis showed that immunochemotherapy decreased the ove... |
QA:79fa99467ef9b1674a3306ec | QAG:8cc953bb60d5df41e876e392 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Another phase III study that focused on ESCC, KEYNOTE-590, showed that ESCC patients with CPS ≥ 10 who received pembrolizumab plus chemotherapy had a superior response rate, PFS, and OS than those with chemotherapy alone; however, there were no statistical differences ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dbea3c954babcd5c3581129a","quotes":["Another phase III study that focused on ESCC, KEYNOTE-590, showed that ESCC ... | [
"CLM:dbea3c954babcd5c3581129a",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:e2e43868d1702bd797c7ec18"
] | [] | [] | {"qa_id":"QA:79fa99467ef9b1674a3306ec","qa_group_id":"QAG:8cc953bb60d5df41e876e392","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Another phase III study that focused on ESCC, KEYNOTE-590, showed ... |
QA:7bbd84120d09da98022aaf0a | QAG:0bc74706442f94c880ca28ce | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Figure 5 Reduced OTUD6B predicted a poor prognosis in ESCC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0aa60de380d08805dcca77fa","quotes":["Figure 5 Reduced OTUD6B predicts a poor prognosis in ESCC patients."],"citat... | [
"CLM:0aa60de380d08805dcca77fa",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:e8735eaa80b9b68a4d823fc3"
] | [] | [] | {"qa_id":"QA:7bbd84120d09da98022aaf0a","qa_group_id":"QAG:0bc74706442f94c880ca28ce","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Figure 5 Reduced OTUD6B predicted a poor prognosis in ESCC patient... |
QA:7c12b70b4a3ab6f9fc3b69d5 | QAG:eca8878e65b4835268fc7ab2 | provenance_qa | paper_evidence_availability | provenance_qa | G023 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34269067? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:34269067","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:34269067"
] | [] | [] | [] | {"qa_id":"QA:7c12b70b4a3ab6f9fc3b69d5","qa_group_id":"QAG:eca8878e65b4835268fc7ab2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G023","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34269067? E... |
QA:7cf3e0b3a9e344d8f1edec7b | QAG:a5253cc230fb3a32f0ad1829 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Finally, we utilized publicly available bulk RNA-seq data from 29 melanoma patients who received anti-PD1 treatment to establish the relationship between the top 50 gene signatures of TREM2+ tumor-associated macrophages in ESCC and resistance to immune checkpoint block... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2ecc9a99eb08b98b12fde622","quotes":["Finally, we utilized publicly available bulk RNA-seq data from 29 melanoma p... | [
"CLM:2ecc9a99eb08b98b12fde622",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:f1a58cb170065bdc9f2ce34b"
] | [] | [] | {"qa_id":"QA:7cf3e0b3a9e344d8f1edec7b","qa_group_id":"QAG:a5253cc230fb3a32f0ad1829","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Finally, we utilized publicly available bulk RNA-seq data from 29 ... |
QA:7d37774118b7db2aa5d039d1 | QAG:e52bec3f1abd17d8e00a80f2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "[ 5d ] In addition, it has been reported that a significant percentage of ESCC patient specimens shows decreased β ‐TrCP expression. β ‐TrCP is involved in the process of protein ubiquitination and its own stability is heavily regulated by this process. For example, ub... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9d5da661646ae1c35e67ce46","quotes":["F‐box proteins are proteins containing at least one F‐box domain, which are ... | [
"CLM:9d5da661646ae1c35e67ce46",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:be631a37cc4245242040880c"
] | [] | [] | {"qa_id":"QA:7d37774118b7db2aa5d039d1","qa_group_id":"QAG:e52bec3f1abd17d8e00a80f2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"[ 5d ] In addition, it has been reported that a significant percen... |
QA:7e19070fd85226cf1fcb24dd | QAG:3329e98b7991fdd5ba4146ab | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Methods A total of 64 patients with advance ESCC receiving first-line ICI + CT at two centers between January 2019 and June 2020 were enrolled in this study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requiremen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ab19eac01b6b9d04ba310cb5","quotes":["Methods A total of 64 patients with advance ESCC receiving first-line ICI + ... | [
"CLM:ab19eac01b6b9d04ba310cb5",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8557514"
] | [
"SPAN:a167e089a3705a7fa86b63ba"
] | [] | [] | {"qa_id":"QA:7e19070fd85226cf1fcb24dd","qa_group_id":"QAG:3329e98b7991fdd5ba4146ab","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Methods A total of 64 patients with advance ESCC receiving first-l... |
QA:7fb800d2cd73afad32f12524 | QAG:2733f4afcd5495734407a852 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "However, few studies have evaluated its efficacy in patients with ESCC who received anti-PD-1 combined with neoadjuvant chemotherapy ( 31 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ex... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:920eeff9e0fea211b0935088","quotes":["However, few studies have evaluated its efficacy in... | [
"CLM:920eeff9e0fea211b0935088",
"CLM:08a48a247c9286d56048a968",
"CLM:11a8bd68e85fd714329111fe"
] | [
"PMCID:PMC9606329",
"PMCID:PMC8262036"
] | [
"SPAN:72099f17d508c1f9bf2adb05",
"SPAN:91fcf26088ed4609657329a5"
] | [
"ASC2:b0e5062d16e7b6fc01dbc769"
] | [
"HYP:DCH:572d9f673d0ec213c72dcdcc"
] | {"qa_id":"QA:7fb800d2cd73afad32f12524","qa_group_id":"QAG:2733f4afcd5495734407a852","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"However, few studies have evaluated its efficacy in patients with ... |
QA:7fcf7ff138b31ad70fb8bfe0 | QAG:eb40a34090263afec7ef3a80 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "3 Recently, immune checkpoint inhibitor (ICI) plus chemotherapy has achieved remarkable results and has become one of the important regimens in advanced malignancies, including ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integra... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c9588dac6e2e73fe526f4c0a","quotes":["3 Recently, immune checkpoint inhibitor (ICI) plus chemotherapy has achieved... | [
"CLM:c9588dac6e2e73fe526f4c0a",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:67b08d5a20d3eaa0bf5306af"
] | [] | [] | {"qa_id":"QA:7fcf7ff138b31ad70fb8bfe0","qa_group_id":"QAG:eb40a34090263afec7ef3a80","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"3 Recently, immune checkpoint inhibitor (ICI) plus chemotherapy ha... |
QA:8468be3a58f3e3dbb8f870bc | QAG:bfc4d3b70be16366832ffd26 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with chemotherapy alone, our pooled analysis showed that the incidence rates of adverse effects were not increased in ESCC patients who received chemo-immunotherapy, suggesting chemo-immunotherapy was a kind of treatment with high efficacy and safety"? Return ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:605a5b00741558b6ebc1bbf6","quotes":["Compared with chemotherapy alone, our pooled analysis showed that the incide... | [
"CLM:605a5b00741558b6ebc1bbf6",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:b7732c3db7dcef78052cd131"
] | [] | [] | {"qa_id":"QA:8468be3a58f3e3dbb8f870bc","qa_group_id":"QAG:bfc4d3b70be16366832ffd26","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with chemotherapy alone, our pooled analysis showed that ... |
QA:858ce946e3690bb1d3494f44 | QAG:1d316981752fa6afdaf6805b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "This retrospective study aims to evaluate the efficacy and safety of anlotinib plus PD-1 blockade as second or further-line therapy for advanced ESCC and explore the mechanism of combination therapy to provide sufficient clinical evidence for the subsequent treatment o... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ba64e8ef17c252eaef4d4f65","quotes":["This retrospective study aims to investigate the efficacy and safety of anlo... | [
"CLM:ba64e8ef17c252eaef4d4f65",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:08fde43f0b62adb972904bc9"
] | [] | [] | {"qa_id":"QA:858ce946e3690bb1d3494f44","qa_group_id":"QAG:1d316981752fa6afdaf6805b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"This retrospective study aims to evaluate the efficacy and safety ... |
QA:894adfb9ddc797a0fc19c185 | QAG:f6d780a9e71f70128a93cdbc | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "9 , 10 , 11 , 12 , 13 , 14 , 15 This increased great confidence for immune checkpoint inhibitors to advance into the field of first‐line treatment of advanced esophageal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:abef27e02f5394bc7b58e5cf","quotes":["9 , 10 , 11 , 12 , 13 , 14 , 15 This increased great confidence for immune c... | [
"CLM:abef27e02f5394bc7b58e5cf",
"CLM:063792c6211f8080df71e9da"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:90972e7b4e90af6eef4e56f6"
] | [] | [] | {"qa_id":"QA:894adfb9ddc797a0fc19c185","qa_group_id":"QAG:f6d780a9e71f70128a93cdbc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"9 , 10 , 11 , 12 , 13 , 14 , 15 This increased great confidence fo... |
QA:89f92aab49465ca6b8410aa5 | QAG:4489a6fd191f04c733b8bee3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "It has been reported that cancer-related inflammation was associated with tumor progression and survival in patients with different types of cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9faecfc8b618bd593a788a7a","quotes":["It has been reported that cancer-related inflammation is significantly assoc... | [
"CLM:9faecfc8b618bd593a788a7a",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:696bbc4347c2e44be0fd5ed3",
"SPAN:88a7f6b29c2cac5010bebb5a"
] | [] | [] | {"qa_id":"QA:89f92aab49465ca6b8410aa5","qa_group_id":"QAG:4489a6fd191f04c733b8bee3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"It has been reported that cancer-related inflammation was associat... |
QA:8c371a7101cb30dde04c8ebf | QAG:fb651eb627fd8dcc76d5781f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the published data from five multicenter RCTs with 1970 advanced ESCC patients, our pooled analysis revealed that PD-1 inhibitors as second-line therapy led to better OS and ORR in advanced ESCC patients than chemotherapy, especially significantly prolonged OS in pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:30381d7ec9b808796a0b1d61","quotes":["In the published data from five multicenter RCTs wi... | [
"CLM:30381d7ec9b808796a0b1d61",
"CLM:08a48a247c9286d56048a968",
"CLM:e3ac951193a24e565f22521d"
] | [
"PMCID:PMC8579527",
"PMCID:PMC10022847"
] | [
"SPAN:b6fcca4729328b49ea369c2b",
"SPAN:357a066db83a60bea9ed48e5"
] | [
"ASC2:8bab2ee79f9c469c8e541172"
] | [] | {"qa_id":"QA:8c371a7101cb30dde04c8ebf","qa_group_id":"QAG:fb651eb627fd8dcc76d5781f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the published data from five multicenter RCTs with 1970 advance... |
QA:8cc2f9414b573e4009765ecf | QAG:80bd530688bfd7fdf8953a62 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Notably, the most recently released data of RATIONALE-306 also showed prolonged OS of tislelizumab plus chemotherapy over chemotherapy in patients with low PD-L1–expressing ESCC in a global manner, 29 which was in line with the results of our meta-analysis"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:35c8d238552ca234dc3c9312","quotes":["Notably, the most recently released data of RATIONALE-306 also showed prolon... | [
"CLM:35c8d238552ca234dc3c9312",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10022847"
] | [
"SPAN:28d5c53b1ea91df94a01b9c2"
] | [] | [] | {"qa_id":"QA:8cc2f9414b573e4009765ecf","qa_group_id":"QAG:80bd530688bfd7fdf8953a62","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Notably, the most recently released data of RATIONALE-306 also sho... |
QA:8e45864f1c7e0af9a0c64c9e | QAG:12311e4d0ae65f1cc38cbfd1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We were pleasantly surprised to find that ESCC patients located in the mid-thoracic segment was associated with a more significant pathological response rate, which may be related to the shorter lesion length and lower lymph node stage at baseline in these patients com... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6d7a93c1c6a63a65323db673","quotes":["We were pleasantly surprised to find that ESCC patients located in the mid-t... | [
"CLM:6d7a93c1c6a63a65323db673",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9606329"
] | [
"SPAN:2461310ab0bd3a9035bcab47"
] | [] | [] | {"qa_id":"QA:8e45864f1c7e0af9a0c64c9e","qa_group_id":"QAG:12311e4d0ae65f1cc38cbfd1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We were pleasantly surprised to find that ESCC patients located in... |
QA:8e460ed2658b7ae7a98c37e8 | QAG:8a99c0c7ff827476218048db | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "055 † decreased hemoglobin, n (%) 6 (9.4%) 4 (12.5%) 2 (6.3%) 0.668 § Normal albumin, n (%) 64 (100%) 32 (100%) 32 (100%) NA Increased leucocyte, n (%) 10 (15.6%) 5 (15.6%) 5 (15.6%) 1.000 † C-reactive protein≥10 mg/L, n (%) 31 (48.4%) 13 (40.6%) 18 (56.3%) 0.211 † Und... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0991831bbf7006fe9faffdbf","quotes":["Table 1 Clinicopathological characteristics of advanced ESCC patients treate... | [
"CLM:0991831bbf7006fe9faffdbf",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8557514"
] | [
"SPAN:ea273b8d1fac66e5d6f1eb24"
] | [] | [] | {"qa_id":"QA:8e460ed2658b7ae7a98c37e8","qa_group_id":"QAG:8a99c0c7ff827476218048db","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"055 † decreased hemoglobin, n (%) 6 (9.4%) 4 (12.5%) 2 (6.3%) 0.66... |
QA:90328dddd716b0b4710e63d6 | QAG:5ab752fa0e4c6b1252cc032e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Radiotherapy is widely applied in each stage of esophageal cancer and has garnered considerable attention in combination with immunotherapy, following the KEYNOTE-001 study, which revealed a superior efficacy of ICI in patients who had previously received radiotherapy ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:77c86199d49e339a6350f59e","quotes":["Radiotherapy is widely applied in each stage of esophageal cancer and has ga... | [
"CLM:77c86199d49e339a6350f59e",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:1bfccf3ce7810102b6bbb093"
] | [] | [] | {"qa_id":"QA:90328dddd716b0b4710e63d6","qa_group_id":"QAG:5ab752fa0e4c6b1252cc032e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Radiotherapy is widely applied in each stage of esophageal cancer ... |
QA:917625a6072c50a142df24a8 | QAG:90008076f0d1122e51d73c47 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients who met the inclusion criteria received at least two cycles of immunochemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dae8e4b53efb4fe9ca215439","quotes":["Patients who met the inclusion criteria received at least two cycles of immu... | [
"CLM:dae8e4b53efb4fe9ca215439",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9326168"
] | [
"SPAN:91dbf6cb80971a02bece5ce1",
"SPAN:da11bc2b2ae129b797f8b9a3"
] | [] | [] | {"qa_id":"QA:917625a6072c50a142df24a8","qa_group_id":"QAG:90008076f0d1122e51d73c47","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients who met the inclusion criteria received at least two cycl... |
QA:93a3dfc413485978498b4166 | QAG:4067bd8ba38969d8d1566694 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the real-world study, the addition of radiotherapy to immunochemotherapy in locally recurrent ESCC prolonged OS (median OS 19.5 vs 7.7 months), while no difference in PFS or OS was observed with or without radiotherapy in the entire cohort ( 124 )"? Return the origi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1e99aad79c23ba5ceae683b0","quotes":["In the real-world study, the addition of radiotherapy to immunochemotherapy ... | [
"CLM:1e99aad79c23ba5ceae683b0",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:1a2406bd4eed4924426a6bb9"
] | [] | [] | {"qa_id":"QA:93a3dfc413485978498b4166","qa_group_id":"QAG:4067bd8ba38969d8d1566694","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the real-world study, the addition of radiotherapy to immunoche... |
QA:93d5dc503efd839d1fa4b791 | QAG:c65e2021c4c9ad0782d2a6fe | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "119 patients with ESCC who received anti-PD-1 inhibitor treatment from December 2018 to September 2020 in Sun Yat-sen University Cancer Center, Guangzhou were included in this retrospective study"? Return the original wording with paper, Claim, and Evidence Span refere... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:61225f13524108717dc99d6a","quotes":["119 patients with ESCC who received anti-PD-1 inhibitor treatment from Decem... | [
"CLM:61225f13524108717dc99d6a",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:203a3dccb0b93fde6413dc53"
] | [] | [] | {"qa_id":"QA:93d5dc503efd839d1fa4b791","qa_group_id":"QAG:c65e2021c4c9ad0782d2a6fe","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"119 patients with ESCC who received anti-PD-1 inhibitor treatment ... |
QA:94b7932ba30706b8c62f5311 | QAG:34177d26c3a11cc1cdb59823 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Based on our data, we found that NLR at 6 weeks post treatment was associated with the response to anti-PD-1 antibody treatment and low NLR after anti-PD-1 treatment seemed to be a favorable factor in the therapeutic effect on anti-PD-1 treatment in ESCC patients, whil... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1ba7d711757749ffff229f94","quotes":["Based on our data, we found that NLR at 6 weeks pos... | [
"CLM:1ba7d711757749ffff229f94",
"CLM:0991831bbf7006fe9faffdbf",
"CLM:6d8b372feb2f9490a744540e",
"CLM:11a8bd68e85fd714329111fe",
"CLM:350aa98892765ca25e7ae951"
] | [
"PMCID:PMC8262036",
"PMCID:PMC8579527",
"PMCID:PMC8557514"
] | [
"SPAN:ad364c2ad690d87e5556b8be",
"SPAN:947e310371175820538cead3",
"SPAN:32049d0c34b0b26f3650b2f3",
"SPAN:91fcf26088ed4609657329a5"
] | [
"ASC2:4ab32b5a5e1ead16208a660d",
"ASC2:f9b07037c11856dd062cf3e9"
] | [
"HYP:DCH:89d84f6c972eac43eae7173b"
] | {"qa_id":"QA:94b7932ba30706b8c62f5311","qa_group_id":"QAG:34177d26c3a11cc1cdb59823","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Based on our data, we found that NLR at 6 weeks post treatment was... |
QA:9a04d819d994bc42ac1d2729 | QAG:3a64b512fb22ca3f3c82bf12 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared to untreated group, the expression level of OTUD6B in ESCC tumors was increased in ATRA‐treated Otud6b WT mice (Figure 7E,F )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f999d5497da391895b66c243","quotes":["Compared to untreated group, the expression level of OTUD6B in ESCC tumors w... | [
"CLM:f999d5497da391895b66c243",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:7d543d5b45658b8bbd89a7aa"
] | [] | [] | {"qa_id":"QA:9a04d819d994bc42ac1d2729","qa_group_id":"QAG:3a64b512fb22ca3f3c82bf12","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared to untreated group, the expression level of OTUD6B in ESC... |
QA:9a95d1892fb4a4892fca8639 | QAG:6fd76496a42f7d5461d33a5e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "25 These studies also showed that patients with advanced ESCC who received immunochemotherapy had significantly higher ORR than those who received chemotherapy alone"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:beba2e7b196b8e853f8a4f6a","quotes":["25 These studies also showed that patients with advanced ESCC who received i... | [
"CLM:beba2e7b196b8e853f8a4f6a",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:5afb8e01239e4d60191e7b11"
] | [] | [] | {"qa_id":"QA:9a95d1892fb4a4892fca8639","qa_group_id":"QAG:6fd76496a42f7d5461d33a5e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"25 These studies also showed that patients with advanced ESCC who ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.